サカイ　リヨウコ   Ryoko Sakai   酒井　良子    所属   医学部 医学科（東京女子医科大学病院）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
掲載誌名	正式名：International journal of rheumatic diseases 略　 称：Int J Rheum Dis ISSNコード：1756185X17561841
掲載区分	国外
巻・号・頁	21(9),pp.1670-1677
著者・共著者	Sakai Ryoko, Kasai Shoko, Hirano Fumio, Harada Sayoko, Kihara Mari, Yokoyama Waka, Tsutsumino Michi, Nagasaka Kenji, Koike Ryuji, Yamanaka Hisashi, Miyasaka Nobuyuki, Harigai Masayoshi
担当区分	筆頭著者
発行年月	2018/09
概要	OBJECTIVE:It is controversial whether the use of biological disease-modifying antirheumatic drugs (DMARDs) increases the risk of herpes zoster (HZ). We aimed to evaluate the risks of HZ in tumor necrosis factor inhibitor (TNFI) and non-TNFI users with rheumatoid arthritis (RA) over 3 years in Japan.METHOD:Using the Japanese health insurance database, we assigned patients with at least one RA diagnostic code and one prescription for any DMARDs (RA cases) recorded between January 2005 and December 2013 to the RA group. We randomly selected five age-, sex-, calendar year- and observation length-matched non-RA cases for each RA case (non-RA group), and assessed associations between RA and HZ. To evaluate the risks of HZ in TNFI and non-TNFI users, we conducted a nested case-control study (NCC) in the RA group.RESULTS:The RA group (n = 6712) had a significantly higher crude incidence rate of HZ than the non-RA group (n = 33 560) (14.2 vs. 8.3/1000 patient-years), and the adjusted odds ratio (95% confidence interval) of the RA versus non-RA groups was 1.43 (1.17-1.75). The NCC demonstrated that use of TNFI, non-TNFI, methotrexate, or immunosuppressive DMARDs did not increase the risks of HZ. Use of corticosteroid ≥ 5 mg/day conveyed a significant risk of HZ in patients with RA.CONCLUSIONS:Rheumatoid arthritis was significantly associated with the development of HZ, and use of corticosteroids ≥ 5 mg/day was identified as a significant risk factor, whereas either TNFI or non-TNFI use were not.
DOI	10.1111/1756-185X.13300
PMID	29667330